Member Info for Oldfortyniner

Thanks for the thoughts. I've done some more digging and found a document on the Pennon website which declares they think they are buying back up to 14.99% of the shares! I still dislike the up to; it sounds like the window displays in shops with a sale on. Up to 75% off can mean next to nothing! However I've decided my plan of action. Assuming the price does remain constant before and after the consolidation I worked out how many shares I'd have if I sell out before and buy back after compared with how many I have after consolidation if I stay in plus extra bought from the divi. Easy really. And either way if there were to be a dip afterwards to buy into it would be even better.

Absolutely my last words on the subject:
Shares now 422,120,000 so after consolidation 281,413,333.
£400,000,000 buys 37,435,657 shares at £10.685 a go.
That's 13.3% of the available shares so shares should rise to £12.10.
Is that better? What a dimwit! Time to go shopping, I can just about cope with that! :-)

Second try:
Shares in issue now 422,120,000,000 so after consolidation 281,413,333,333.
£400,000,000 at £10.685 a go would buy 37,435,657 shares which now doesn't look all that significant.
My thanks still apply, but I'll shut up and get back in my box!

I think my maths is awful so ignore all that!

Great discussion on dividends. You've certainly given me food for thought so huge thanks guys.
I've just done some thinking about the buyback programme with UP TO (my emphasis) £0.4Bn to spend in the market and 422.12Bn shares currently in issue ie 422,120,000 shares. After the 2 for 3 consolidation there will therefore be 281,413,333 shares in issue.
At the notional share price of £10.685 that means the buy back is targeting up to 9.25% of the shares. The buy back will drive an equivalent price increase which should therefore take the share price up to about £11.97 if it all comes about in this way.
This I would suggest needs to be part of anyone's thinking though there are a lot of variables.
How much will they actually spend? How long will it take? Where will the price go anyway with the new company structure following the acquisition of Bristol Water?
Perhaps most significantly, did I get the numbers right?

Don't worry. Have got it, thanks!

Cebo, any chance of giving the text of the article which is behind an account setting?

Fairdealer, sorry for my absence on other interests. Money does talk; it's what the market works on. Everyone has their price so I see no merit in digging a hole for ourselves on where that tipping point might be.
The Company is obliged to act in the interests of its shareholders, which doesn't necessarily have to be simply taking the quick buck. Their can be risks for the company itself in succumbing to an approach, not to mention the impact on the continued availability of its produce. The hope that I was expressing was that if the company placed any offer before its shareholders as it would have to do, the board could itself recommend rejection and/or individual and institutional shareholders could make a value judgement on whether the price to be gained was worth surrendering the company to foreign hands.
Others have conjectured on the strategic importance issue and whether the mythical buyer might be American or whoever. If governmental involvement came about to prevent a strategic loss I'm not sure it would really matter who it was. I think I'd rather hope this scenario simply didn't get put to the test.

Fairdealer, I do not argue here with what you said. However one of the positives which I didn't mention in my earlier post in the TGR thread is that this company is loosening the world's dependency on China for a commodity which is going to be vital for the future. In my view it would be a travesty if this company were to fall to a Chinese bid. If such a proposal were to be placed before shareholders I would hope the response would be no.

This is an amazing company. We're only six months on from the IPO and the price has now more than doubled with big potential still ahead of us. I was cautious when I got in at the IPO (hindsight is a wonderful thing!) but jolly glad I made a couple of top ups on the way. With revenue earning production from the off, expansion under way and to come, a responsible ESG approach, and R&D taking it into new high value arenas there are a lot of positives here.
Good luck to all.

Easy to skip lightly over this sentence in Scaredy's update but does it infer that a grand plan is already in place with the DH?
"The firm has been in talks with the Department of Health to roll out its test in the UK and it is also in active discussion with distributors in 25 EU markets."

Being over a certain age I've already had both my vaccinations done, but agree with your prioritization. GL for Sunday.
I think it was an HL item I read that commented that this week many traders have been away from their desks as it's half term week, so things would be a little other than normal. This all goes to reinforce the maxim that patience is a virtue, especially for investors. We look forwards; fingers crossed for June 21.

Excuse the apparent familiarity but alas, Smithy, depending on where you topped up, you're probably going to be heartily brassed off with today's opening. What looks like a shift in position by Morgan Stanley doesn't seem to have done it any favours. You have my commiserations. I haven't changed my holding, but am staying in there for the sort of future you are looking forward to, and this does not look a very pretty start to the end of the week.

It's a lovely day, the sun is shining in the garden. Ciao!

28th May:
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, notes speculation regarding the ongoing CE mark submission for its SARS-CoV-2 Antigen Lateral Flow Test to the Medicines and Healthcare products Regulatory Agency ("MHRA") by its partner Mologic Limited ("Mologic").

To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so.

Rocquet, you give a robust and authoritative response, which I do not have the technical knowledge of the processes involved to rebut. However that is not what the RNS says.

If you think we're not waiting for a CE mark response try re-reading the last RNS:
the CE mark submission to MHRA is still ongoing and Avacta will update the market when it is a position to do so.

Thanks Muck - I won't ask how you got that! :-)

Did anyone manage to read the annual report on the website? If it was there it seems no longer to be so. The obvious link still refers to the 2020 job and gives an 'error 404 - page not found' message.

Thanks for the canine humour guys - enjoyed that!
If R4 came up with a hit rate of 94/100 they were using different figures from what was in the link AgentB gave us. There it seems to be 88% success which means 12% false negatives (samples missed) and there were 16% false positives( samples that were not infections at all). That doesn't sound very reassuring to me, nor does the closing comment "The research is at an early stage so it still needs to be reviewed by other scientists before it can be published and, in the next phase of the study, tried out on infected people - rather than bits of sock." Bleagh!